JP2006528236A - ジプラシドンを用いて認知を増強する方法 - Google Patents
ジプラシドンを用いて認知を増強する方法 Download PDFInfo
- Publication number
- JP2006528236A JP2006528236A JP2006530660A JP2006530660A JP2006528236A JP 2006528236 A JP2006528236 A JP 2006528236A JP 2006530660 A JP2006530660 A JP 2006530660A JP 2006530660 A JP2006530660 A JP 2006530660A JP 2006528236 A JP2006528236 A JP 2006528236A
- Authority
- JP
- Japan
- Prior art keywords
- fluoro
- chloro
- substituted
- quinolyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 title claims abstract description 16
- 229960000607 ziprasidone Drugs 0.000 title claims abstract description 16
- 230000019771 cognition Effects 0.000 title claims abstract description 10
- 241000124008 Mammalia Species 0.000 claims abstract description 46
- 238000000034 method Methods 0.000 claims abstract description 30
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 21
- 239000002253 acid Substances 0.000 claims abstract description 20
- 206010003805 Autism Diseases 0.000 claims abstract description 12
- 208000020706 Autistic disease Diseases 0.000 claims abstract description 12
- 206010012289 Dementia Diseases 0.000 claims abstract description 12
- 208000036626 Mental retardation Diseases 0.000 claims abstract description 12
- 230000009329 sexual behaviour Effects 0.000 claims abstract description 12
- 208000020925 Bipolar disease Diseases 0.000 claims abstract description 8
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims abstract description 6
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 6
- 238000013019 agitation Methods 0.000 claims abstract description 6
- 208000014674 injury Diseases 0.000 claims abstract description 6
- 208000028017 Psychotic disease Diseases 0.000 claims abstract description 5
- 230000016571 aggressive behavior Effects 0.000 claims abstract description 5
- 206010009259 cleft lip Diseases 0.000 claims abstract description 5
- -1 Benzoisothiazolyl Chemical group 0.000 claims description 136
- 125000001153 fluoro group Chemical group F* 0.000 claims description 54
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 44
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 32
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 20
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims description 20
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 20
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 20
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 20
- 125000005493 quinolyl group Chemical group 0.000 claims description 20
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 20
- 125000001041 indolyl group Chemical group 0.000 claims description 19
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims description 11
- 125000001624 naphthyl group Chemical group 0.000 claims description 11
- 125000005874 benzothiadiazolyl group Chemical group 0.000 claims description 10
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 10
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 10
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 10
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 10
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 10
- 230000003542 behavioural effect Effects 0.000 claims description 7
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 231100000867 compulsive behavior Toxicity 0.000 claims description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 abstract description 35
- 239000000126 substance Substances 0.000 abstract description 13
- 241000282412 Homo Species 0.000 abstract description 11
- 230000006399 behavior Effects 0.000 abstract description 7
- 208000024891 symptom Diseases 0.000 abstract description 7
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 150
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 61
- 239000007787 solid Substances 0.000 description 47
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 42
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 41
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 38
- 238000006243 chemical reaction Methods 0.000 description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 37
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 33
- 238000002844 melting Methods 0.000 description 32
- 230000008018 melting Effects 0.000 description 32
- 229910052757 nitrogen Inorganic materials 0.000 description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 23
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 23
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 239000010410 layer Substances 0.000 description 20
- 239000000047 product Substances 0.000 description 19
- 229910000029 sodium carbonate Inorganic materials 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 239000012267 brine Substances 0.000 description 14
- 239000000741 silica gel Substances 0.000 description 14
- 229910002027 silica gel Inorganic materials 0.000 description 14
- 235000009518 sodium iodide Nutrition 0.000 description 14
- 229910052938 sodium sulfate Inorganic materials 0.000 description 14
- 235000011152 sodium sulphate Nutrition 0.000 description 14
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 12
- CPLWKJWNQCWKQV-UHFFFAOYSA-N 6-(2-bromoethyl)-3h-1,3-benzoxazol-2-one Chemical compound BrCCC1=CC=C2NC(=O)OC2=C1 CPLWKJWNQCWKQV-UHFFFAOYSA-N 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 239000003480 eluent Substances 0.000 description 10
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 8
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 8
- PCKPVGOLPKLUHR-UHFFFAOYSA-N OH-Indolxyl Natural products C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 description 8
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 241000400611 Eucalyptus deanei Species 0.000 description 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 6
- VNICFCQJUVFULD-UHFFFAOYSA-N 1-(1-naphthalenyl)piperazine Chemical compound C1CNCCN1C1=CC=CC2=CC=CC=C12 VNICFCQJUVFULD-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- MKYNHKOAYQRSBD-UHFFFAOYSA-N dioxouranium;nitric acid Chemical compound O=[U]=O.O[N+]([O-])=O.O[N+]([O-])=O MKYNHKOAYQRSBD-UHFFFAOYSA-N 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- HPXJIGZLXHQSGU-UHFFFAOYSA-N 5-(2-chloroethyl)-1,3-dihydroindol-2-one Chemical compound ClCCC1=CC=C2NC(=O)CC2=C1 HPXJIGZLXHQSGU-UHFFFAOYSA-N 0.000 description 4
- 0 C*N1C*N(*)CC1 Chemical compound C*N1C*N(*)CC1 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- WXJWBEAGVWVEDM-UHFFFAOYSA-N 5-(2-chloroacetyl)-1,3-dihydroindol-2-one Chemical compound ClCC(=O)C1=CC=C2NC(=O)CC2=C1 WXJWBEAGVWVEDM-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 125000002346 iodo group Chemical group I* 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229920000137 polyphosphoric acid Polymers 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- KOOKQPMRBFPCJH-UHFFFAOYSA-N 1-benzyl-4-(6-fluoronaphthalen-1-yl)piperazine Chemical compound C=1C=CC2=CC(F)=CC=C2C=1N(CC1)CCN1CC1=CC=CC=C1 KOOKQPMRBFPCJH-UHFFFAOYSA-N 0.000 description 2
- LOEVNCQTVTVGKM-UHFFFAOYSA-N 4-(2-oxo-3h-1,3-benzoxazol-6-yl)butyl 2,2,2-trifluoroacetate Chemical compound FC(F)(F)C(=O)OCCCCC1=CC=C2NC(=O)OC2=C1 LOEVNCQTVTVGKM-UHFFFAOYSA-N 0.000 description 2
- JZJFRQGXFVVZPK-UHFFFAOYSA-N 4-piperazin-1-yl-2,1,3-benzothiadiazole Chemical compound C1CNCCN1C1=CC=CC2=NSN=C12 JZJFRQGXFVVZPK-UHFFFAOYSA-N 0.000 description 2
- LTKOVYPSNBPPDB-UHFFFAOYSA-N 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1,3-dihydroindol-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CC(NC4=CC=3)=O)=NSC2=C1 LTKOVYPSNBPPDB-UHFFFAOYSA-N 0.000 description 2
- OUOBVBYOAFEOKS-UHFFFAOYSA-N 6-fluoronaphthalen-1-amine Chemical compound FC1=CC=C2C(N)=CC=CC2=C1 OUOBVBYOAFEOKS-UHFFFAOYSA-N 0.000 description 2
- PRGBEFGWVMWEGQ-UHFFFAOYSA-N 6-fluoronaphthalene-1-carboxylic acid Chemical compound FC1=CC=C2C(C(=O)O)=CC=CC2=C1 PRGBEFGWVMWEGQ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- KRDOFMHJLWKXIU-UHFFFAOYSA-N ID11614 Chemical compound C1CNCCN1C1=NSC2=CC=CC=C12 KRDOFMHJLWKXIU-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010037180 Psychiatric symptoms Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- QOYUUAUHYUIMDO-UHFFFAOYSA-N ethenyl 4-(2,1,3-benzothiadiazol-4-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC=C)CCN1C1=CC=CC2=NSN=C12 QOYUUAUHYUIMDO-UHFFFAOYSA-N 0.000 description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- CRVNOUFSHGQXRN-UHFFFAOYSA-N 1,3-dihydroindol-2-one hydrate hydrochloride Chemical compound O.Cl.C1=CC=C2NC(=O)CC2=C1 CRVNOUFSHGQXRN-UHFFFAOYSA-N 0.000 description 1
- LWPVQTZPRWKELS-UHFFFAOYSA-N 1-(4-methoxynaphthalen-1-yl)piperazine Chemical compound C12=CC=CC=C2C(OC)=CC=C1N1CCNCC1 LWPVQTZPRWKELS-UHFFFAOYSA-N 0.000 description 1
- FBPPFIPXMJEJCU-UHFFFAOYSA-N 1-(5,6,7,8-tetrahydronaphthalen-1-yl)piperazine Chemical compound C1CCCC2=C1C=CC=C2N1CCNCC1 FBPPFIPXMJEJCU-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- ZCOVJSFXVKKOII-UHFFFAOYSA-N 1-ethoxy-5-[2-(4-naphthalen-1-ylpiperazin-1-yl)ethyl]indole hydrate hydrochloride Chemical compound O.Cl.C1(=CC=CC2=CC=CC=C12)N1CCN(CC1)CCC=1C=C2C=CN(C2=CC1)OCC ZCOVJSFXVKKOII-UHFFFAOYSA-N 0.000 description 1
- ZYVYPNZFOCZLEM-UHFFFAOYSA-N 1-naphthalen-1-ylpiperazin-4-ium;chloride Chemical compound Cl.C1CNCCN1C1=CC=CC2=CC=CC=C12 ZYVYPNZFOCZLEM-UHFFFAOYSA-N 0.000 description 1
- DZWBPVWZCQJMGW-UHFFFAOYSA-N 1-piperazin-1-ylphthalazine Chemical compound C1CNCCN1C1=NN=CC2=CC=CC=C12 DZWBPVWZCQJMGW-UHFFFAOYSA-N 0.000 description 1
- MIYLVJAXQYOWJA-UHFFFAOYSA-N 2-(4-chlorobutyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CCCCCl MIYLVJAXQYOWJA-UHFFFAOYSA-N 0.000 description 1
- PTTPXKJBFFKCEK-UHFFFAOYSA-N 2-Methyl-4-heptanone Chemical compound CC(C)CC(=O)CC(C)C PTTPXKJBFFKCEK-UHFFFAOYSA-N 0.000 description 1
- 125000005999 2-bromoethyl group Chemical group 0.000 description 1
- RJQWWOOJMDUVFE-UHFFFAOYSA-N 2-chloro-1-(1,3,3-trimethoxy-2H-indol-5-yl)ethanone Chemical compound ClCC(=O)C=1C=C2C(CN(C2=CC1)OC)(OC)OC RJQWWOOJMDUVFE-UHFFFAOYSA-N 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- YGGUKPPJTCGLMX-UHFFFAOYSA-N 3-(1,2-benzothiazol-3-yloxy)-1,2-benzothiazole Chemical group S1N=C(C2=C1C=CC=C2)OC1=NSC2=C1C=CC=C2 YGGUKPPJTCGLMX-UHFFFAOYSA-N 0.000 description 1
- XOJIUEFCVNDEGY-UHFFFAOYSA-N 3-[4-[2-(1,3-dimethoxyindol-5-yl)ethyl]piperazin-1-yl]-1,2-benzothiazole Chemical compound S1N=C(C2=C1C=CC=C2)N2CCN(CC2)CCC=2C=C1C(=CN(C1=CC2)OC)OC XOJIUEFCVNDEGY-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- LWTBDMCUMXLYOI-UHFFFAOYSA-N 4-(4-bromobutanoyl)-3H-1,3-benzoxazol-2-one Chemical compound BrCCCC(=O)C1=CC=CC2=C1NC(O2)=O LWTBDMCUMXLYOI-UHFFFAOYSA-N 0.000 description 1
- YIDMPLFTBQMVAQ-UHFFFAOYSA-N 4-(4-methylpiperazin-1-yl)-2,1,3-benzothiadiazole Chemical compound C1CN(C)CCN1C1=CC=CC2=NSN=C12 YIDMPLFTBQMVAQ-UHFFFAOYSA-N 0.000 description 1
- GRHQDJDRGZFIPO-UHFFFAOYSA-N 4-bromobutanoic acid Chemical compound OC(=O)CCCBr GRHQDJDRGZFIPO-UHFFFAOYSA-N 0.000 description 1
- PVABLRWKKBXIDZ-UHFFFAOYSA-N 5-(2-bromoethyl)benzimidazol-2-one Chemical compound C1=C(CCBr)C=CC2=NC(=O)N=C21 PVABLRWKKBXIDZ-UHFFFAOYSA-N 0.000 description 1
- GCULOOUUFWFQNZ-UHFFFAOYSA-N 5-(2-chloroacetyl)-1-ethyl-3h-indol-2-one Chemical compound ClCC(=O)C1=CC=C2N(CC)C(=O)CC2=C1 GCULOOUUFWFQNZ-UHFFFAOYSA-N 0.000 description 1
- RRFQHTVONYSCEQ-UHFFFAOYSA-N 5-(2-chloroacetyl)-1-methyl-3h-indol-2-one Chemical compound ClCC(=O)C1=CC=C2N(C)C(=O)CC2=C1 RRFQHTVONYSCEQ-UHFFFAOYSA-N 0.000 description 1
- XKMBOKBRGRDGTF-UHFFFAOYSA-N 5-(2-chloroacetyl)-6-fluoro-3,3-dimethyl-1h-indol-2-one Chemical compound FC1=C(C(=O)CCl)C=C2C(C)(C)C(=O)NC2=C1 XKMBOKBRGRDGTF-UHFFFAOYSA-N 0.000 description 1
- WHCVJHOPBFFOON-UHFFFAOYSA-N 5-(2-chloroethyl)-1,3-dimethoxyindole Chemical compound C1=C(CCCl)C=C2C(OC)=CN(OC)C2=C1 WHCVJHOPBFFOON-UHFFFAOYSA-N 0.000 description 1
- WKEZOIZTNJYCOJ-UHFFFAOYSA-N 5-(2-chloroethyl)-1-ethyl-3h-indol-2-one Chemical compound ClCCC1=CC=C2N(CC)C(=O)CC2=C1 WKEZOIZTNJYCOJ-UHFFFAOYSA-N 0.000 description 1
- XRLXFMZCUVDADB-UHFFFAOYSA-N 5-(2-chloroethyl)-1-methyl-3h-indol-2-one Chemical compound ClCCC1=CC=C2N(C)C(=O)CC2=C1 XRLXFMZCUVDADB-UHFFFAOYSA-N 0.000 description 1
- LYLJGWHKMPQQDA-UHFFFAOYSA-N 5-(2-chloroethyl)-6-fluoro-1,3-dihydroindol-2-one Chemical compound C1=C(CCCl)C(F)=CC2=C1CC(=O)N2 LYLJGWHKMPQQDA-UHFFFAOYSA-N 0.000 description 1
- OAJVBIORPADAOB-UHFFFAOYSA-N 5-(2-chloroethyl)-6-fluoro-3,3-dimethyl-1h-indol-2-one Chemical compound FC1=C(CCCl)C=C2C(C)(C)C(=O)NC2=C1 OAJVBIORPADAOB-UHFFFAOYSA-N 0.000 description 1
- BTHUDFYOBJFKRQ-UHFFFAOYSA-N 5-(2-chloroethyl)-7-fluoro-1,3-dihydroindol-2-one Chemical compound FC1=CC(CCCl)=CC2=C1NC(=O)C2 BTHUDFYOBJFKRQ-UHFFFAOYSA-N 0.000 description 1
- MDIITGQMVDKDTE-UHFFFAOYSA-N 5-(2-chloroethyl)spiro[1h-indole-3,1'-cyclopentane]-2-one Chemical compound C12=CC(CCCl)=CC=C2NC(=O)C21CCCC2 MDIITGQMVDKDTE-UHFFFAOYSA-N 0.000 description 1
- DKZVMJZADWLCEK-UHFFFAOYSA-N 5-(4-chlorobutyl)-7-fluoro-1,3-dihydroindol-2-one Chemical compound FC1=CC(CCCCCl)=CC2=C1NC(=O)C2 DKZVMJZADWLCEK-UHFFFAOYSA-N 0.000 description 1
- GEJKYGSJUJTWOZ-UHFFFAOYSA-N 5-[2-(4-naphthalen-1-ylpiperazin-1-yl)ethyl]-1,3-dihydroindol-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CC(NC4=CC=3)=O)=CC=CC2=C1 GEJKYGSJUJTWOZ-UHFFFAOYSA-N 0.000 description 1
- OLHPDERTOIKVER-UHFFFAOYSA-N 5-[2-(4-naphthalen-1-ylpiperazin-1-yl)ethyl]benzimidazol-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=CC4=NC(N=C4C=3)=O)=CC=CC2=C1 OLHPDERTOIKVER-UHFFFAOYSA-N 0.000 description 1
- ARUJUHZDRPXMRW-UHFFFAOYSA-N 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-1-ethyl-3h-indol-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)C(CC=3C=C4CC(=O)N(CC)C4=CC=3)CC)=NSC2=C1 ARUJUHZDRPXMRW-UHFFFAOYSA-N 0.000 description 1
- ODISJICXHNXUDC-UHFFFAOYSA-N 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-7-fluoro-1,3-dihydroindol-2-one;hydrate Chemical compound O.C1=CC=C2C(N3CCN(CC3)C(CC=3C=C(F)C=4NC(=O)CC=4C=3)CC)=NSC2=C1 ODISJICXHNXUDC-UHFFFAOYSA-N 0.000 description 1
- XGSCDCBZXBOKQG-UHFFFAOYSA-N 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1-chloro-3h-indol-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CC(=O)N(C4=CC=3)Cl)=NSC2=C1 XGSCDCBZXBOKQG-UHFFFAOYSA-N 0.000 description 1
- NCYBUBNVBAHNLA-UHFFFAOYSA-N 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1-ethyl-3h-indol-2-one;hydrochloride Chemical compound Cl.C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CC(=O)N(C4=CC=3)CC)=NSC2=C1 NCYBUBNVBAHNLA-UHFFFAOYSA-N 0.000 description 1
- NZDBKBRIBJLNNT-UHFFFAOYSA-N 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one;hydron;chloride Chemical compound Cl.C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 NZDBKBRIBJLNNT-UHFFFAOYSA-N 0.000 description 1
- JGPGYNVUNNJHSV-UHFFFAOYSA-N 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-fluoro-1,3-dihydroindol-2-one;hydrate;hydrochloride Chemical compound O.Cl.C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3F)=NSC2=C1 JGPGYNVUNNJHSV-UHFFFAOYSA-N 0.000 description 1
- AHXHIRWJGGSOTN-UHFFFAOYSA-N 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-7-fluoro-1,3-dihydroindol-2-one;hydrochloride Chemical compound Cl.C1=CC=C2C(N3CCN(CC3)CCC=3C=C(C=4NC(=O)CC=4C=3)F)=NSC2=C1 AHXHIRWJGGSOTN-UHFFFAOYSA-N 0.000 description 1
- KWJYLSMUUIXRBO-UHFFFAOYSA-N 6-(2-bromoethyl)-1,3-benzothiazole 1-oxide Chemical compound BrCCC1=CC=C2N=CS(=O)C2=C1 KWJYLSMUUIXRBO-UHFFFAOYSA-N 0.000 description 1
- IMMWCMHVIKCYSW-UHFFFAOYSA-N 6-(4-bromobutanoyl)-3h-1,3-benzoxazol-2-one Chemical compound BrCCCC(=O)C1=CC=C2NC(=O)OC2=C1 IMMWCMHVIKCYSW-UHFFFAOYSA-N 0.000 description 1
- CYVQZXCJZRDKLT-UHFFFAOYSA-N 6-(4-chlorobutyl)-3h-1,3-benzoxazol-2-one Chemical compound ClCCCCC1=CC=C2NC(=O)OC2=C1 CYVQZXCJZRDKLT-UHFFFAOYSA-N 0.000 description 1
- KHEYJRDJVYKTEY-UHFFFAOYSA-N 6-[2-(4-naphthalen-1-ylpiperazin-1-yl)ethyl]-1,3-benzothiazole 1-oxide Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4N=CS(C4=C3)=O)=CC=CC2=C1 KHEYJRDJVYKTEY-UHFFFAOYSA-N 0.000 description 1
- DPNXNSJFFDGJRR-UHFFFAOYSA-N 6-[2-(4-naphthalen-1-ylpiperazin-1-yl)ethyl]-3h-1,3-benzoxazol-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(OC4=C3)=O)=CC=CC2=C1 DPNXNSJFFDGJRR-UHFFFAOYSA-N 0.000 description 1
- PZLGBASBFOSOOX-UHFFFAOYSA-N 6-[2-(4-phthalazin-1-ylpiperazin-1-yl)ethyl]-3h-1,3-benzoxazol-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(OC4=C3)=O)=NN=CC2=C1 PZLGBASBFOSOOX-UHFFFAOYSA-N 0.000 description 1
- IEXKTBKUFHXFRV-UHFFFAOYSA-N 6-[2-(4-quinolin-6-ylpiperazin-1-yl)ethyl]-3h-1,3-benzoxazol-2-one Chemical compound N1=CC=CC2=CC(N3CCN(CC3)CCC3=CC=C4NC(OC4=C3)=O)=CC=C21 IEXKTBKUFHXFRV-UHFFFAOYSA-N 0.000 description 1
- XVWLLSAJVOZBEN-UHFFFAOYSA-N 6-[2-(4-quinolin-8-ylpiperazin-1-yl)ethyl]-3h-1,3-benzoxazol-2-one Chemical compound C1=CN=C2C(N3CCN(CC3)CCC3=CC=C4NC(OC4=C3)=O)=CC=CC2=C1 XVWLLSAJVOZBEN-UHFFFAOYSA-N 0.000 description 1
- ZWSBCAMYZMCUFX-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-3h-1,3-benzoxazol-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(OC4=C3)=O)=NSC2=C1 ZWSBCAMYZMCUFX-UHFFFAOYSA-N 0.000 description 1
- ZZVDGMSWFXVSLJ-UHFFFAOYSA-N 6-[2-[4-(4-methoxynaphthalen-1-yl)piperazin-1-yl]ethyl]-3h-1,3-benzoxazol-2-one Chemical compound C12=CC=CC=C2C(OC)=CC=C1N1CCN(CCC=2C=C3OC(=O)NC3=CC=2)CC1 ZZVDGMSWFXVSLJ-UHFFFAOYSA-N 0.000 description 1
- IPCKNBMIHWBUOB-UHFFFAOYSA-N 6-[2-[4-(5,6,7,8-tetrahydronaphthalen-1-yl)piperazin-1-yl]ethyl]-3h-1,3-benzoxazol-2-one Chemical compound C1CCCC2=C1C=CC=C2N(CC1)CCN1CCC1=CC=C2NC(=O)OC2=C1 IPCKNBMIHWBUOB-UHFFFAOYSA-N 0.000 description 1
- DFQBINVRYBRGFZ-UHFFFAOYSA-N 6-[2-[4-(6-hydroxyquinolin-8-yl)piperazin-1-yl]ethyl]-3h-1,3-benzoxazol-2-one Chemical compound N1=CC=CC2=CC(O)=CC(N3CCN(CCC=4C=C5OC(=O)NC5=CC=4)CC3)=C21 DFQBINVRYBRGFZ-UHFFFAOYSA-N 0.000 description 1
- ZOOOZSQMGJVIIH-UHFFFAOYSA-N 6-[4-(4-naphthalen-1-ylpiperazin-1-yl)butyl]-3h-1,3-benzoxazol-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCCCC3=CC=C4NC(OC4=C3)=O)=CC=CC2=C1 ZOOOZSQMGJVIIH-UHFFFAOYSA-N 0.000 description 1
- ZTQQXEPZEYIVDK-UHFFFAOYSA-N 6-chloro-5-(2-chloroethyl)-1,3-dihydroindol-2-one Chemical compound C1=C(Cl)C(CCCl)=CC2=C1NC(=O)C2 ZTQQXEPZEYIVDK-UHFFFAOYSA-N 0.000 description 1
- GSSFATVYFHRGQZ-UHFFFAOYSA-N 6-fluoro-5-[2-(4-naphthalen-1-ylpiperazin-1-yl)ethyl]-1,3-dihydroindol-2-one;hydrochloride Chemical compound Cl.C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3F)=CC=CC2=C1 GSSFATVYFHRGQZ-UHFFFAOYSA-N 0.000 description 1
- WNCJNGKFHAUUFK-UHFFFAOYSA-N 7-fluoro-5-[2-(4-naphthalen-1-ylpiperazin-1-yl)ethyl]-1,3-dihydroindol-2-one;hydrochloride Chemical compound Cl.C1=CC=C2C(N3CCN(CC3)CCC=3C=C(C=4NC(=O)CC=4C=3)F)=CC=CC2=C1 WNCJNGKFHAUUFK-UHFFFAOYSA-N 0.000 description 1
- WUOMFIBXTAXXRP-UHFFFAOYSA-N 8-piperazin-1-ylquinazoline Chemical compound C1CNCCN1C1=CC=CC2=CN=CN=C12 WUOMFIBXTAXXRP-UHFFFAOYSA-N 0.000 description 1
- ULPZONMXSOOPJO-UHFFFAOYSA-N 8-piperazin-1-ylquinolin-6-ol Chemical compound C=12N=CC=CC2=CC(O)=CC=1N1CCNCC1 ULPZONMXSOOPJO-UHFFFAOYSA-N 0.000 description 1
- DCUZDOXGNVJQQL-UHFFFAOYSA-N 8-piperazin-1-ylquinoline Chemical compound C1CNCCN1C1=CC=CC2=CC=CN=C12 DCUZDOXGNVJQQL-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- NXQBACKBJAUKBE-UHFFFAOYSA-N Cl.C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CC(=O)N(C4=CC=3)C)=NSC2=C1 Chemical compound Cl.C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CC(=O)N(C4=CC=3)C)=NSC2=C1 NXQBACKBJAUKBE-UHFFFAOYSA-N 0.000 description 1
- QCOILZJLIGGWCL-UHFFFAOYSA-N Cl.S1N=C(C2=C1C=CC=C2)N2CCN(CC2)CCC=2C=C1C(C=NC1=CC2F)(OC)OC Chemical compound Cl.S1N=C(C2=C1C=CC=C2)N2CCN(CC2)CCC=2C=C1C(C=NC1=CC2F)(OC)OC QCOILZJLIGGWCL-UHFFFAOYSA-N 0.000 description 1
- CSRQFPRTIASEFU-UHFFFAOYSA-N Cl.S1N=C(C2=C1C=CC=C2)N2CCN(CC2)CCC=2C=C1C(CN(C1=CC2)OC)(OC)OC Chemical compound Cl.S1N=C(C2=C1C=CC=C2)N2CCN(CC2)CCC=2C=C1C(CN(C1=CC2)OC)(OC)OC CSRQFPRTIASEFU-UHFFFAOYSA-N 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- AGWYKDNFUABOKC-UHFFFAOYSA-N S1N=C(C2=C1C=CC=C2)N2CCN(CC2)CCC=2C=C1C(C=NC1=CC2)(OC)OC.Cl Chemical compound S1N=C(C2=C1C=CC=C2)N2CCN(CC2)CCC=2C=C1C(C=NC1=CC2)(OC)OC.Cl AGWYKDNFUABOKC-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- AZRWNJFEUSHORT-UHFFFAOYSA-N benzyl-bis(2-chloroethyl)azanium;chloride Chemical compound [Cl-].ClCC[NH+](CCCl)CC1=CC=CC=C1 AZRWNJFEUSHORT-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000037410 cognitive enhancement Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- PQLFROTZSIMBKR-UHFFFAOYSA-N ethenyl carbonochloridate Chemical compound ClC(=O)OC=C PQLFROTZSIMBKR-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 1
- 229960002868 mechlorethamine hydrochloride Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 230000019818 neurotransmitter uptake Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 150000005623 oxindoles Chemical class 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47137903P | 2003-05-16 | 2003-05-16 | |
| PCT/IB2004/001600 WO2004100956A1 (en) | 2003-05-16 | 2004-05-05 | Method for enhancing cognition using ziprasidone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006528236A true JP2006528236A (ja) | 2006-12-14 |
| JP2006528236A5 JP2006528236A5 (https=) | 2007-06-21 |
Family
ID=33452442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006530660A Pending JP2006528236A (ja) | 2003-05-16 | 2004-05-05 | ジプラシドンを用いて認知を増強する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20050014764A1 (https=) |
| EP (1) | EP1626722A1 (https=) |
| JP (1) | JP2006528236A (https=) |
| AR (1) | AR044337A1 (https=) |
| BR (1) | BRPI0419067A (https=) |
| CA (2) | CA2625837A1 (https=) |
| MX (1) | MXPA05012325A (https=) |
| TW (1) | TW200507847A (https=) |
| WO (1) | WO2004100956A1 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010532382A (ja) * | 2007-06-29 | 2010-10-07 | エモリー・ユニバーシテイ | 神経保護のためのｎｍｄａ受容体拮抗薬 |
| JP2011520815A (ja) * | 2008-05-09 | 2011-07-21 | エモリー・ユニバーシテイ | 精神神経障害治療のためのｎｍｄａ受容体拮抗薬 |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE424825T1 (de) | 2001-07-20 | 2009-03-15 | Psychogenics Inc | Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten |
| EP1617832B1 (en) | 2003-04-29 | 2008-03-12 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
| MY145694A (en) | 2005-04-11 | 2012-03-30 | Xenon Pharmaceuticals Inc | Spiroheterocyclic compounds and their uses as therapeutic agents |
| MY144968A (en) * | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| CN101370488B (zh) | 2005-11-22 | 2012-07-18 | 奥雷西根治疗公司 | 增加胰岛素敏感性的组合物 |
| US20100222353A1 (en) * | 2006-01-27 | 2010-09-02 | Pfizer Products Inc. | Aminophthalazine derivative compounds |
| EP2520567A3 (en) * | 2006-02-23 | 2012-12-12 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| JP2010506853A (ja) * | 2006-10-12 | 2010-03-04 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 疼痛などのナトリウムチャネル媒介性の疾患の処置のための、スピロ（［３，２−フロ］ピリジン−３，３’−インドール）−２’（１’ｈ）−オン誘導体および関連化合物 |
| AR063280A1 (es) * | 2006-10-12 | 2009-01-21 | Xenon Pharmaceuticals Inc | Uso de compuestos de espiro-oxindol como agentes terapeuticos |
| AU2007307635A1 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents |
| KR20170077291A (ko) | 2006-11-09 | 2017-07-05 | 오렉시젠 세러퓨틱스 인크. | 단위 용량 팩키지 |
| WO2009158114A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| CA2741024A1 (en) * | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| CN105218565A (zh) | 2008-10-17 | 2016-01-06 | 泽农医药公司 | 螺羟吲哚化合物及其作为治疗剂的用途 |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| US20110086899A1 (en) * | 2009-10-14 | 2011-04-14 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
| MX2012004373A (es) * | 2009-10-14 | 2012-06-28 | Xenon Pharmaceuticals Inc | Metodos sinteticos para compuestos espiro-oxoindol. |
| MX344303B (es) | 2010-01-11 | 2016-12-13 | Orexigen Therapeutics Inc | Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor. |
| CA2788440A1 (en) | 2010-02-26 | 2011-09-01 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
| CA2799154A1 (en) | 2010-05-12 | 2011-11-17 | Abbvie Inc. | Indazole inhibitors of kinase |
| CN110893181A (zh) | 2012-06-06 | 2020-03-20 | 纳丙药业有限责任公司 | 治疗超重和肥胖症的方法 |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| TW201636017A (zh) | 2015-02-05 | 2016-10-16 | 梯瓦製藥國際有限責任公司 | 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法 |
| WO2016191316A1 (en) * | 2015-05-22 | 2016-12-01 | Stem Cell Theranostics, Inc. | Modulation of drug-induced cardiotoxicity |
| KR20240161147A (ko) | 2022-03-14 | 2024-11-12 | 슬랩 파마슈티컬스 엘엘씨 | 다중 사이클릭 화합물 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63301861A (ja) * | 1987-03-02 | 1988-12-08 | ファイザー・インコーポレーテッド | ピペラジニルー複素環式化合物 |
| JPH11180874A (ja) * | 1997-09-05 | 1999-07-06 | Pfizer Prod Inc | トゥレット症候群の治療用薬剤 |
| JPH11509865A (ja) * | 1996-05-07 | 1999-08-31 | ファイザー インク． | ５―（２―（４―（１，２―ベンズイソチアゾール―３―イル）―１―ピペラジニル）エチル）―６―クロロ―１，３―ジヒドロ―２（１ｈ）―インドール―２―オン（＝ジプラシドン）のメシレート三水和物、その調製法およびドーパミンｄ２アンタゴニストとしてのその使用法 |
| JPH11246409A (ja) * | 1997-12-18 | 1999-09-14 | Pfizer Prod Inc | 精神医学的な疾患または障害の治療法 |
| JP2001503031A (ja) * | 1996-09-23 | 2001-03-06 | イーライ・リリー・アンド・カンパニー | 精神病の治療のための組み合わせ療法 |
| JP2002541098A (ja) * | 1999-04-06 | 2002-12-03 | セプラコア インコーポレーテッド | ジプラシドン代謝産物を用いる神経弛緩薬性障害および関連障害を治療するための方法および組成物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4883795A (en) * | 1988-01-22 | 1989-11-28 | Pfizer Inc. | Piperazinyl-heterocyclic compounds |
| US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US6387904B2 (en) * | 1998-05-18 | 2002-05-14 | Pfizer Inc | Method of treating glaucoma and ischemic retinopathy |
| WO2000059459A1 (en) * | 1999-03-30 | 2000-10-12 | Lion Corporation | Hairdye composition of single preparation type containing an oxidase |
-
2004
- 2004-05-05 EP EP04731234A patent/EP1626722A1/en not_active Withdrawn
- 2004-05-05 CA CA002625837A patent/CA2625837A1/en not_active Abandoned
- 2004-05-05 CA CA002525323A patent/CA2525323A1/en not_active Abandoned
- 2004-05-05 MX MXPA05012325A patent/MXPA05012325A/es unknown
- 2004-05-05 BR BRPI0419067-0A patent/BRPI0419067A/pt not_active IP Right Cessation
- 2004-05-05 JP JP2006530660A patent/JP2006528236A/ja active Pending
- 2004-05-05 WO PCT/IB2004/001600 patent/WO2004100956A1/en not_active Ceased
- 2004-05-14 AR ARP040101652A patent/AR044337A1/es unknown
- 2004-05-14 TW TW093113727A patent/TW200507847A/zh unknown
- 2004-05-14 US US10/846,797 patent/US20050014764A1/en not_active Abandoned
-
2008
- 2008-04-28 US US12/110,522 patent/US20080269246A1/en not_active Abandoned
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63301861A (ja) * | 1987-03-02 | 1988-12-08 | ファイザー・インコーポレーテッド | ピペラジニルー複素環式化合物 |
| JPH11509865A (ja) * | 1996-05-07 | 1999-08-31 | ファイザー インク． | ５―（２―（４―（１，２―ベンズイソチアゾール―３―イル）―１―ピペラジニル）エチル）―６―クロロ―１，３―ジヒドロ―２（１ｈ）―インドール―２―オン（＝ジプラシドン）のメシレート三水和物、その調製法およびドーパミンｄ２アンタゴニストとしてのその使用法 |
| JP2001503031A (ja) * | 1996-09-23 | 2001-03-06 | イーライ・リリー・アンド・カンパニー | 精神病の治療のための組み合わせ療法 |
| JPH11180874A (ja) * | 1997-09-05 | 1999-07-06 | Pfizer Prod Inc | トゥレット症候群の治療用薬剤 |
| JPH11246409A (ja) * | 1997-12-18 | 1999-09-14 | Pfizer Prod Inc | 精神医学的な疾患または障害の治療法 |
| JP2002541098A (ja) * | 1999-04-06 | 2002-12-03 | セプラコア インコーポレーテッド | ジプラシドン代謝産物を用いる神経弛緩薬性障害および関連障害を治療するための方法および組成物 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010532382A (ja) * | 2007-06-29 | 2010-10-07 | エモリー・ユニバーシテイ | 神経保護のためのｎｍｄａ受容体拮抗薬 |
| JP2011520815A (ja) * | 2008-05-09 | 2011-07-21 | エモリー・ユニバーシテイ | 精神神経障害治療のためのｎｍｄａ受容体拮抗薬 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2625837A1 (en) | 2004-11-25 |
| US20050014764A1 (en) | 2005-01-20 |
| EP1626722A1 (en) | 2006-02-22 |
| AR044337A1 (es) | 2005-09-07 |
| BRPI0419067A (pt) | 2007-12-11 |
| US20080269246A1 (en) | 2008-10-30 |
| WO2004100956A1 (en) | 2004-11-25 |
| MXPA05012325A (es) | 2006-01-30 |
| CA2525323A1 (en) | 2004-11-25 |
| TW200507847A (en) | 2005-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006528236A (ja) | ジプラシドンを用いて認知を増強する方法 | |
| US4831031A (en) | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity | |
| EP0931547B1 (en) | Piperazinyl-heterocyclic compounds in the treatment of dementia | |
| US4883795A (en) | Piperazinyl-heterocyclic compounds | |
| CZ281257B6 (cs) | Heterocyklické arylpiperazinylové deriváty a způsob jejich přípravy | |
| JP2007502856A (ja) | 精神病性障害および抑うつ性障害の治療 | |
| JP2007522095A (ja) | ジプラシドンを用いた不安の治療 | |
| JP2007516955A (ja) | 双極性障害および関連症候の治療 | |
| JP3004969B2 (ja) | トゥレット症候群の治療用薬剤 | |
| US6387904B2 (en) | Method of treating glaucoma and ischemic retinopathy | |
| EP0985414B1 (en) | Medicament for the treatment of glaucoma and ischemic retinopathy | |
| EP1757292A1 (en) | Method of treating ocd and tic disorders | |
| HK1087332A (en) | Treatment of bipolar disorders and associated symptoms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070426 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070426 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100712 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110105 |